Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
STRATA Skin Sciences, Inc. (SSKN)
USD0.09
+0.00 (+0.00%)
US OTC Healthcare Medical - Devices
Address
5 Walnut Grove Drive 19044
Horsham, PA, US
Horsham, PA, US
CEO
Dolev Rafaeli
Website
strataskinsciences.com
IPO
2005-11-03
CIK 1051514 ISIN US86272A3059
Description
STRATA Skin Sciences, Inc. is an innovative medical technology enterprise dedicated to the development, commercialization, and marketing of advanced products specifically designed for treating a range of dermatologic conditions. The company operates through two main divisions: Dermatology Recurring Procedures and Dermatology Procedures Equipment. With a substantial global footprint, STRATA Skin Sciences distributes its solutions across the United States, Europe, the Middle East, Asia, Australia, South Africa, and both Central and South America. Its notable product portfolio includes the XTRAC and Pharos excimer laser systems, VTRAC lamp systems, and TheraClear treatment solutions. These technologies are instrumental in addressing common skin ailments such as psoriasis, vitiligo, and acne, among others. Domestically, the company engages directly with physicians for product distribution, while leveraging a network of international distributors to reach markets beyond the U.S. Established in 1989 and headquartered in Horsham, Pennsylvania, the company adopted its current name, STRATA Skin Sciences, Inc., in January 2016, having previously operated as MELA Sciences, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.09
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
14.9K
Beta
-0.08
Float Shares
2.19M
Free Float %
47.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +24.32% | -5.88% | +6.60% | -58.97% | -90.48% | -87.30% | -93.73% | -98.45% | -98.94% | -99.65% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.09
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-11.63
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-8.5% Q4'25: -3.0% (vs Q4'24)
-
EPS growth Medical - Devices: +28.5%-419.2% Q4'25: +108.2% (vs Q4'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%-18.6% Q4'25: -5.9% (vs Q4'24)
-
EBIT margin Medical - Devices: +6.2%-19.0% Q4'25: +0.4% (vs Q4'24)
-
ROIC Medical - Devices: +3.3%-51.8% Q4'25: +1.1% (vs Q4'24)
-
Share dilution Medical - Devices: 0.0%+22.2% Q4'25: -84.5% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-11.89× Q4'25: 4.31× (vs Q4'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
18.50M
est: 17.50M (+5.7%)
|
31.76M
est: 30.90M (+2.8%)
|
31.45M
est: 30.80M (+2.1%)
|
29.86M
est: 29.86M (0.0%)
|
31.59M
est: 31.29M (+1.0%)
|
23.09M
est: 23.10M (0.0%)
|
29.98M
est: 29.89M (+0.3%)
|
36.16M
est: 35.38M (+2.2%)
|
33.36M
est: 32.73M (+1.9%)
|
33.56M
est: 32.96M (+1.8%)
|
30.70M
est: 20.35M (+50.8%)
|
22.18M
22.18M – 22.18M
+9.0% YoY
|
24.40M
24.40M – 24.40M
+10.0% YoY
|
| EBITDA |
-12.42M
est: -342.4K (-3,529.0%)
|
2.77M
est: -604.5K (+558.1%)
|
4.54M
est: -602.5K (+853.0%)
|
2.04M
est: -584.1K (+449.6%)
|
1.81M
est: -612.1K (+395.9%)
|
-15.0K
est: -451.9K (+96.7%)
|
1.73M
est: -584.8K (+395.5%)
|
1.13M
est: -692.1K (+263.0%)
|
-3.38M
est: -927.8K (-264.3%)
|
-2.84M
est: -934.3K (-204.2%)
|
-1.37M
est: -576.8K (-137.2%)
|
-628.7K
-628.7K – -628.7K
-9.0% YoY
|
-691.7K
-691.7K – -691.7K
-10.0% YoY
|
| EBIT |
-16.48M
est: -3.14M (-425.4%)
|
-3.60M
est: -5.54M (+35.0%)
|
-1.80M
est: -5.52M (+67.4%)
|
-3.36M
est: -5.35M (+37.3%)
|
-3.01M
est: -5.61M (+46.3%)
|
-3.93M
est: -4.14M (+5.1%)
|
-2.36M
est: -5.36M (+56.0%)
|
-4.56M
est: -6.34M (+28.1%)
|
-9.28M
est: -6.00M (-54.8%)
|
-8.15M
est: -6.04M (-35.0%)
|
-5.84M
est: -3.73M (-56.5%)
|
-4.06M
-4.06M – -4.06M
-9.0% YoY
|
-4.47M
-4.47M – -4.47M
-10.0% YoY
|
| Net Income |
-27.91M
est: -5.62B (+99.5%)
|
-3.34M
est: -685.29M (+99.5%)
|
-21.51M
est: -3.22B (+99.3%)
|
-4.03M
est: -55.20M (+92.7%)
|
-3.79M
est: -47.59M (+92.0%)
|
-4.41M
est: -55.84M (+92.1%)
|
-2.71M
est: -28.55M (+90.5%)
|
-5.55M
est: -78.05M (+92.9%)
|
-10.83M
est: -110.42M (+90.2%)
|
-10.09M
est: -64.41M (+84.3%)
|
-6.26M
est: -83.71M (+92.5%)
|
-59.99M
-59.99M – -59.99M
+28.3% YoY
|
-44.65M
-44.65M – -44.65M
+25.6% YoY
|
| SGA |
19.22M
est: 12.61M (+52.4%)
|
20.79M
est: 22.27M (-6.6%)
|
18.65M
est: 22.19M (-16.0%)
|
19.41M
est: 21.51M (-9.8%)
|
22.28M
est: 22.55M (-1.2%)
|
16.94M
est: 16.65M (+1.7%)
|
22.82M
est: 21.54M (+5.9%)
|
25.39M
est: 25.49M (-0.4%)
|
23.46M
est: 23.75M (-1.2%)
|
23.59M
est: 23.92M (-1.4%)
|
23.30M
est: 14.77M (+57.7%)
|
16.10M
16.10M – 16.10M
+9.0% YoY
|
17.71M
17.71M – 17.71M
+10.0% YoY
|
| EPS |
-163.50
est: -147.50 (-10.8%)
|
-3.77
est: -18.00 (+79.1%)
|
-3.26
est: -84.50 (+96.1%)
|
-0.15
est: -1.45 (+89.7%)
|
-0.12
est: -1.25 (+90.4%)
|
-0.13
est: -1.47 (+91.1%)
|
-0.08
est: -0.75 (+89.4%)
|
-0.16
est: -2.05 (+92.2%)
|
-0.31
est: -2.37 (+86.9%)
|
-0.26
est: -1.39 (+81.2%)
|
-1.35
est: -1.80 (+25.0%)
|
-1.29
-1.29 – -1.29
+28.3% YoY
|
-0.96
-0.96 – -0.96
+25.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.09M
OE per share TTM
-0.21
Owner's Yield
-539.86%
Maintenance CapEx ratio
678.73%
Maint CapEx / Avg PPE
28.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
32
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BARCLAYS GLOBAL INVESTORS, NA | 3.39M | 6.59% | 1.71M | — | 1.80M | — | BK | Delaware | 2013-01-24 | ↗ |
| 2 | Peter Kolchinsky | 2.99M | 7.90% | 2.99M | — | 2.99M | — | IN | United States | 2013-02-15 | ↗ |
| 3 | RA Capital Management, LLC | 2.99M | 7.90% | 2.99M | — | 2.99M | — | IA | Massachusetts | 2013-02-15 | ↗ |
| 4 | Daniel Mack | 2.77M | 9.20% | — | 2.77M | — | — | HC | USA | 2019-02-14 | ↗ |
| 5 | Nantahala Capital Management, LLC | 2.77M | 9.20% | — | 2.77M | — | — | IA | MA | 2019-02-14 | ↗ |
| 6 | Wilmot B. Harkey | 2.77M | 9.20% | — | 2.77M | — | — | HC | USA | 2019-02-14 | ↗ |
| 7 | 22NW Fund GP, LLC | 2.00M | 5.80% | — | — | 2.00M | — | OO | DELAWARE | 2022-01-14 | ↗ |
| 8 | 22NW Fund, LP | 2.00M | 5.80% | — | — | 2.00M | — | PN | DELAWARE | 2022-01-14 | ↗ |
| 9 | 22NW GP, Inc. | 2.00M | 5.80% | — | — | 2.00M | — | CO | DELAWARE | 2022-01-14 | ↗ |
| 10 | 22NW, LP | 2.00M | 5.80% | — | — | 2.00M | — | PN | DELAWARE | 2022-01-14 | ↗ |
| 11 | Aron R. English | 2.00M | 5.80% | — | — | 2.00M | — | IN | DELAWARE | 2022-01-14 | ↗ |
| 12 | RA Capital Healthcare Fund, L.P. | 1.73M | 4.60% | 1.73M | — | 1.73M | — | PN | Citizenship or Place of Organization | 2013-02-15 | ↗ |
| 13 | Benjamin Natter | 1.66M | 4.90% | — | 1.66M | — | — | HC, IN | United States | 2021-02-16 | ↗ |
| 14 | Kent Lake Capital LLC | 1.66M | 4.90% | — | 1.66M | — | — | IA, HC | Delaware | 2021-02-16 | ↗ |
| 15 | Kent Lake Partners LP | 1.66M | 4.90% | — | 1.66M | — | — | PN | Delaware | 2021-02-16 | ↗ |
| 16 | BAM Capital, LLC | 1.51M | 5.99% | — | 1.51M | — | 1.51M | OO | Delaware, U.S.A. | 2011-01-11 | ↗ |
| 17 | BAM Management, LLC | 1.51M | 5.99% | — | 1.51M | — | 1.51M | OO | Delaware, U.S.A. | 2011-01-11 | ↗ |
| 18 | BAM Opportunity Fund, L.P. | 1.51M | 5.99% | — | 1.51M | — | 1.51M | PN | Delaware, U.S.A. | 2011-01-11 | ↗ |
| 19 | Ross Berman | 1.51M | 5.99% | — | 1.51M | — | 1.51M | IN | United States of America | 2011-01-11 | ↗ |
| 20 | Dr. Jeffrey R. Jay, M.D. | 601.3K | 9.99% | — | 601.3K | — | 601.3K | IN | USA | 2014-10-24 | ↗ |
| 21 | Great Point Partners, LLC | 601.3K | 9.99% | — | 601.3K | — | 601.3K | IA | USA | 2014-10-24 | ↗ |
| 22 | Mr. David Kroin | 601.3K | 9.99% | — | 601.3K | — | 601.3K | IN | USA | 2014-10-24 | ↗ |
| 23 | Hal Mintz | 407.2K | 9.99% | — | 407.2K | — | 10.00 | IN | United States of America | 2018-01-02 | ↗ |
| 24 | Sabby Management, LLC | 407.2K | 9.99% | — | 407.2K | — | 10.00 | OO | Delaware | 2018-01-02 | ↗ |
| 25 | AMH Equity LLC | 170.0K | 4.17% | 13.5K | — | 13.5K | — | PN | New York, USA | 2018-01-23 | ↗ |
| 26 | Leviticus Partners, L.P. | 170.0K | 4.17% | 156.5K | — | 156.5K | — | PN | Delaware, USA | 2018-01-23 | ↗ |
| 27 | Sabby Volatility Warrant Master Fund, Ltd. | 72.1K | 1.77% | — | 72.1K | — | 10.00 | CO | Cayman Islands | 2018-01-02 | ↗ |
| 28 | Sabby Healthcare Master Fund, Ltd. | 8.00 | 8.22% | — | 335.1K | — | 10.00 | CO | Cayman Islands | 2018-01-02 | ↗ |
| 29 | BAM Offshore Management, LLC | — | 0.00% | — | — | — | — | OO | Delaware, U.S.A. | 2011-01-11 | ↗ |
| 30 | BAM Total Return Master Fund, Ltd. | — | 0.00% | — | — | — | — | OO | Cayman Islands | 2011-01-11 | ↗ |
| 31 | Menora Mivtachim Holdings Ltd. | — | 0.00% | — | — | — | — | CO | Israel | 2020-02-12 | ↗ |
| 32 | Menora Mivtachim Insurance Ltd. | — | 0.00% | — | — | — | — | CO | Israel | 2020-02-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.67
Neutral
Ratio by volume
0.35
Bearish
Buys
2
Sells
3
Shares acquired
5.0K
Shares disposed
14.1K
Cash buys
2.00
Cash sales
3.00
Net activity
-9,094
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-18 | Rubinstein Samuel | Director | P-Purchase | A | Common Stock | 2,832 | 1.41 | 4.0K | 8,766 | D | ↗ |
| 2025-11-17 | Rubinstein Samuel | Director | S-Sale | D | Common Stock | 5,500 | 1.32 | 7.3K | 12,360 | D | ↗ |
| 2025-05-13 | Rafaeli Dolev | Director / Officer | A-Award | A | SSKN Stock Options | 58,000 | 2.55 | 147.9K | 232,557 | D | ↗ |
| 2025-05-13 | Gov Shmuel | Officer | A-Award | A | SSKN Stock Options | 40,000 | 2.55 | 102.0K | 137,125 | D | ↗ |
| 2025-05-13 | Gillings John T | Officer | A-Award | A | SSKN Stock Options | 30,000 | 2.55 | 76.5K | 30,000 | D | ↗ |
| 2024-11-13 | Gov Shmuel | Officer | — | D | Employee Stock Option | 54,339 | 1.46 | 79.3K | 0 | — | ↗ |
| 2024-11-13 | Gillings John T | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-29 | Allgeier Christina L | Director | A-Award | A | SSKN Stock Options | 20,000 | 3.18 | 63.5K | 20,000 | D | ↗ |
| 2024-07-15 | Rafaeli Dolev | Director / Officer | P-Purchase | A | Common Stock | 19,100 | 3.14 | 60.0K | 143,156 | — | ↗ |
| 2024-07-15 | Geiger Uri | Director / 10% Owner | P-Purchase | A | Common Stock | 230,573 | 3.14 | 724.0K | 1,441,835 | — | ↗ |
| 2024-07-15 | Accelmed Partners, L.P. | 10% Owner | P-Purchase | A | Common Stock | 230,573 | 3.14 | 724.0K | 1,441,835 | — | ↗ |
| 2023-12-01 | Gov Shmuel | Officer | P-Purchase | A | SSKN Common Stock | 562 | 0.45 | 252.90 | 14,900 | — | ↗ |
| 2023-11-22 | Gov Shmuel | Officer | — | D | Employee Stock Option | 66,666 | 2.46 | 164.0K | 0 | — | ↗ |
| 2023-11-21 | Lesovitz Christopher | Officer | A-Award | A | Employee Stock Option | 337,500 | 0.50 | 168.8K | 787,500 | — | ↗ |
| 2023-11-21 | Gov Shmuel | Officer | A-Award | A | Employee Stock Option | 416,250 | 0.50 | 208.1K | 971,250 | — | ↗ |
| 2023-11-16 | Rubinstein Samuel | Director | S-Sale | D | Common Stock | 1,000 | 0.32 | 320.00 | 177,602 | — | ↗ |
| 2023-10-30 | Rafaeli Dolev | Director / Officer | A-Award | A | SSKN Stock Options | 1,745,569 | 0.53 | 925.2K | 1,745,569 | — | ↗ |
| 2023-10-26 | Yaniv Irit | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-26 | Rubinstein Samuel | Director | A-Award | A | SSKN Stock Options | 20,000 | 0.53 | 10.6K | 20,000 | — | ↗ |
| 2023-10-26 | Cafran Wayne | Director | A-Award | A | SSKN Stock Options | 20,000 | 0.53 | 10.6K | 20,000 | — | ↗ |
| 2023-08-16 | 22NW, LP | 10% Owner | P-Purchase | A | Common Stock | 1,853,056 | 0.55 | 1.02M | 5,369,954 | — | ↗ |
| 2023-08-10 | Moccia Robert Joseph | Director / Officer | P-Purchase | A | SSKN Common Stock | 42,000 | 0.67 | 28.3K | 235,300 | — | ↗ |
| 2023-08-10 | Lesovitz Christopher | Officer | P-Purchase | A | SSKN Common Stock | 10,000 | 0.67 | 6.7K | 38,282 | — | ↗ |
| 2023-07-05 | Walker Patricia S | Director | A-Award | A | SSKN Common Stock | 36,408 | 1.03 | 37.5K | 89,894 | — | ↗ |
| 2023-07-05 | STRANG DOUGLAS | Director | A-Award | A | SSKN Common Stock | 33,981 | 1.03 | 35.0K | 86,877 | — | ↗ |
| 2023-07-05 | SHAMIR NACHUM | Director | A-Award | A | SSKN Common Stock | 38,835 | 1.03 | 40.0K | 289,871 | — | ↗ |
| 2023-07-05 | Rubinstein Samuel | Director | A-Award | A | SSKN Common Stock | 33,981 | 1.03 | 35.0K | 178,602 | — | ↗ |
| 2023-07-05 | Humphries William D. | Director | A-Award | A | SSKN Common Stock | 36,408 | 1.03 | 37.5K | 109,724 | — | ↗ |
| 2023-04-03 | Moccia Robert Joseph | Director / Officer | A-Award | A | Employee Stock Option | 75,000 | 1.06 | 79.5K | 75,000 | — | ↗ |
| 2023-04-03 | Lesovitz Christopher | Officer | A-Award | A | Employee Stock Options | 100,000 | 1.06 | 106.0K | 100,000 | — | ↗ |
| 2023-04-03 | Gov Shmuel | Officer | A-Award | A | Employee Stock Option | 70,000 | 1.06 | 74.2K | 70,000 | — | ↗ |
| 2023-03-30 | Gov Shmuel | Officer | — | D | Employee Stock Option | 70,000 | 1.45 | 101.5K | 0 | — | ↗ |
| 2022-07-01 | SHAMIR NACHUM | Director | A-Award | A | SSKN Common Stock | 43,244 | 0.93 | 40.0K | 251,036 | — | ↗ |
| 2022-07-01 | Rubinstein Samuel | Director | A-Award | A | SSKN Common Stock | 37,838 | 0.93 | 35.0K | 144,621 | — | ↗ |
| 2022-06-30 | Walker Patricia S | Director | A-Award | A | SSKN Common Stock | 40,541 | 0.93 | 37.5K | 73,486 | — | ↗ |
| 2022-06-30 | STRANG DOUGLAS | Director | A-Award | A | SSKN Common Stock | 37,838 | 0.93 | 35.0K | 72,896 | — | ↗ |
| 2022-06-15 | Rubinstein Samuel | Director | P-Purchase | A | SSKN Common Stock | 1,050 | 1.04 | 1.1K | 106,783 | — | ↗ |
| 2022-06-04 | Gov Shmuel | Officer | — | D | Employee Stock Option | 55,490 | 1.93 | 107.1K | 0 | — | ↗ |
| 2022-05-12 | Lesovitz Christopher | Director / Officer | P-Purchase | A | SSKN Common Stock | 23,131 | 1.12 | 25.9K | 23,131 | — | ↗ |
| 2022-03-31 | Walker Patricia S | Director | A-Award | A | STRATA Restricted Stock Units | 3,189 | 0.00 | — | 23,189 | — | ↗ |
| 2022-03-31 | STRANG DOUGLAS | Director | A-Award | A | STRATA Restricted Stock Units | 5,952 | 0.00 | — | 25,952 | — | ↗ |
| 2022-03-30 | Moccia Robert Joseph | Director / Officer | A-Award | A | Employee Stock Option | 60,000 | 0.00 | — | 1,792,590 | — | ↗ |
| 2022-03-30 | Lesovitz Christopher | Director / Officer | A-Award | A | STRATA Stock Options (right to buy) | 100,000 | 0.00 | — | 350,000 | — | ↗ |
| 2022-03-25 | Humphries William D. | Director | P-Purchase | A | SSKN Common Stock | 16,950 | 1.73 | 29.4K | 484,440 | — | ↗ |
| 2022-03-24 | Moccia Robert Joseph | Director / Officer | P-Purchase | A | SSKN Common Stock | 33,300 | 1.57 | 52.4K | 1,665,890 | — | ↗ |
| 2022-03-24 | Humphries William D. | Director | P-Purchase | A | SSKN Common Stock | 14,783 | 1.58 | 23.4K | 467,490 | — | ↗ |
| 2022-02-14 | Walker Patricia S | Director | A-Award | A | SSKN Non-Qualified Stock Options | 20,000 | 1.48 | 29.6K | 20,000 | — | ↗ |
| 2021-11-03 | STRANG DOUGLAS | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-27 | STRANG DOUGLAS | Director | A-Award | A | SSKN Non-Qualified Stock Options | 20,000 | 1.80 | 36.0K | 20,000 | — | ↗ |
| 2021-10-18 | Lesovitz Christopher | Officer | A-Award | A | STRATA Stock Option (right to buy) | 250,000 | 1.88 | 470.0K | 250,000 | — | ↗ |
| 2021-09-08 | SHAMIR NACHUM | Director | P-Purchase | A | SSKN Common Stock | 2,382 | 1.46 | 3.5K | 166,908 | — | ↗ |
| 2021-09-07 | SHAMIR NACHUM | Director | P-Purchase | A | SSKN Common Stock | 9,270 | 1.41 | 13.1K | 147,578 | — | ↗ |
| 2021-08-20 | Humphries William D. | Director | A-Award | A | Non-Qualified Stock Option Agreement for SSKN Common Stock | 411,124 | 1.42 | 583.8K | 452,707 | — | ↗ |
| 2021-07-20 | Via LuAnn | Director | A-Award | A | SSKN Common Stock | 34,878 | 0.00 | — | 106,584 | — | ↗ |
| 2021-07-20 | SHAMIR NACHUM | Director | A-Award | A | SSKN Common Stock | 32,520 | 0.00 | — | 107,595 | — | ↗ |
| 2021-07-20 | Rubinstein Samuel | Director | A-Award | A | SSKN Common Stock | 28,455 | 0.00 | — | 80,553 | — | ↗ |
| 2021-07-20 | Humphries William D. | Director | A-Award | A | SSKN Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2021-04-12 | Humphries William D. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-01 | Moccia Robert Joseph | Director / Officer | A-Award | A | Employee Stock Option | 1,632,590 | 1.73 | 2.82M | 1,632,590 | — | ↗ |
| 2020-11-13 | HILL MATTHEW C | Officer | A-Award | A | SSKN Stock Options (right to buy) | 150,000 | 1.46 | 219.0K | 150,000 | — | ↗ |
| 2020-10-09 | NAVARRO SAMUEL E | Director | M-Exempt | A | SSKN Common Stock | 15,000 | 1.29 | 19.4K | 66,136 | — | ↗ |
| 2020-06-07 | Gov Shmuel | Officer | — | D | Employee Stock Option | 15,000 | 3.75 | 56.3K | 0 | — | ↗ |
| 2019-11-22 | Via LuAnn | Director | A-Award | A | SSKN Common Stock | 14,228 | 0.00 | — | 71,706 | — | ↗ |
| 2019-11-22 | SHAMIR NACHUM | Director | A-Award | A | SSKN Common Stock | 16,260 | 0.00 | — | 75,075 | — | ↗ |
| 2019-11-22 | Rubinstein Samuel | Director | A-Award | A | SSKN Common Stock | 14,228 | 0.00 | — | 52,098 | — | ↗ |
| 2019-11-22 | Rafaeli Dolev | Director / Officer | A-Award | A | SSKN Stock Options (right to buy) | 300,000 | 2.46 | 738.0K | 3,270,877 | — | ↗ |
| 2019-11-22 | NAVARRO SAMUEL E | Director | A-Award | A | SSKN Common Stock | 14,228 | 0.00 | — | 51,136 | — | ↗ |
| 2019-11-22 | HILL MATTHEW C | Officer | A-Award | A | SSKN Stock Options (right to buy) | 150,000 | 2.46 | 369.0K | 400,000 | — | ↗ |
| 2019-11-22 | GILL DAVID N | Director | A-Award | A | SSKN Common Stock | 18,293 | 0.00 | — | 64,694 | — | ↗ |
| 2019-11-21 | Via LuAnn | Director | P-Purchase | A | SSKN Common Stock | 5,000 | 2.50 | 12.5K | 35,570 | — | ↗ |
| 2018-06-15 | Rafaeli Dolev | Director / Officer | J-Other | A | SSKN Common Stock | 5,814 | 1.09 | 6.3K | 5,814 | — | ↗ |
| 2018-06-15 | Geiger Uri | Director | J-Other | A | SSKN Common Stock | 75,590 | 1.09 | 82.4K | 12,122,627 | — | ↗ |
| 2018-06-15 | Accelmed Growth Partners, L.P. | 10% Owner | J-Other | A | Common Stock, $0.001 par value per share | 75,590 | 1.09 | 82.4K | 12,112,627 | — | ↗ |
| 2018-06-14 | Via LuAnn | Director | P-Purchase | A | SSKN Common Stock | 5,000 | 1.95 | 9.8K | 5,000 | — | ↗ |
| 2018-06-14 | HILL MATTHEW C | Officer | P-Purchase | A | SSKN Common Stock | 1,812 | 1.95 | 3.5K | 10,000 | — | ↗ |
| 2018-06-08 | Via LuAnn | Director | P-Purchase | A | SSKN Common Stock | 5,000 | 2.00 | 10.0K | 5,000 | — | ↗ |
| 2018-06-08 | SHAMIR NACHUM | Director | A-Award | A | STRATA Restricted Stock Units | 28,986 | 2.07 | 60.0K | 28,986 | — | ↗ |
| 2018-06-08 | Rubinstein Samuel | Director | A-Award | A | STRATA Restricted Stock Units | 26,570 | 2.07 | 55.0K | 26,570 | — | ↗ |
| 2018-06-08 | NAVARRO SAMUEL E | Director | A-Award | A | STRATA Restricted Stock Units | 16,908 | 2.07 | 35.0K | 16,908 | — | ↗ |
| 2018-06-08 | Geiger Uri | Director | A-Award | A | STRATA Restricted Stock Units | 19,324 | 2.07 | 40.0K | 19,324 | — | ↗ |
| 2018-06-08 | GILL DAVID N | Director | A-Award | A | STRATA Restricted Stock Units | 26,570 | 2.07 | 55.0K | 26,570 | — | ↗ |
| 2018-06-05 | NAVARRO SAMUEL E | Director | P-Purchase | A | SSKN Common Stock | 5,600 | 1.99 | 11.1K | 20,000 | — | ↗ |
| 2018-05-30 | SHAMIR NACHUM | Director | — | D | SSKN Common Stock | 0 | 0.00 | — | 29,829 | — | ↗ |
| 2018-05-30 | Rubinstein Samuel | Director | — | D | SSKN Common Stock | 0 | 0.00 | — | 11,300 | — | ↗ |
| 2018-05-30 | Geiger Uri | Director | — | I | SSKN Common Stock | 0 | 0.00 | — | 12,037,037 | — | ↗ |
| 2018-05-30 | GILL DAVID N | Director | — | D | SSKN Common Stock | 0 | 0.00 | — | 15,000 | — | ↗ |
| 2018-05-29 | Accelmed Growth Partners, L.P. | 10% Owner | — | I | Common Stock, $0.001 par value per share | 0 | 0.00 | — | 12,037,037 | — | ↗ |
| 2018-05-23 | Rafaeli Dolev | Director / Officer | A-Award | A | STRATA Stock Options (right to buy) | 1,413,249 | 1.66 | 2.35M | 1,413,249 | — | ↗ |
| 2018-05-23 | HILL MATTHEW C | Officer | A-Award | A | STRATA Stock Option (right to buy) | 250,000 | 1.66 | 415.0K | 250,000 | — | ↗ |
| 2018-05-21 | COYNE JAMES L | Director | P-Purchase | A | SSKN Common Stock | 3,000 | 1.68 | 5.0K | 3,000 | — | ↗ |
| 2018-05-15 | HILL MATTHEW C | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-04-10 | Rafaeli Dolev | Director / Officer | — | D | SSKN Stock Options | 1,557,628 | 1.12 | 1.74M | 0 | — | ↗ |
| 2017-12-01 | Via LuAnn | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2017-12-01 | Swintek Kathryn B | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2017-12-01 | STONE DAVID K | Director | A-Award | A | STRATA Non Qualified Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2017-12-01 | ODONNELL JEFFREY F | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2017-12-01 | NAVARRO SAMUEL E | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2017-12-01 | COYNE JAMES L | Director | A-Award | A | STRATA Skin Non-Qualified Stock Option (right to buy) | 15,000 | 1.29 | 19.4K | 15,000 | — | ↗ |
| 2017-05-10 | COYNE JAMES L | Director | A-Award | A | Stock Option (right to buy) | 11,250 | 2.78 | 31.3K | 11,250 | — | ↗ |
| 2016-12-06 | Via LuAnn | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options | 75,000 | 0.55 | 41.3K | 75,000 | — | ↗ |
| 2016-12-06 | Swintek Kathryn B | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options | 75,000 | 0.55 | 41.3K | 75,000 | — | ↗ |
| 2016-12-06 | STONE DAVID K | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options | 75,000 | 0.55 | 41.3K | 75,000 | — | ↗ |
| 2016-12-06 | ODONNELL JEFFREY F | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options | 75,000 | 0.55 | 41.3K | 75,000 | — | ↗ |
| 2016-12-06 | NAVARRO SAMUEL E | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options | 75,000 | 0.55 | 41.3K | 75,000 | — | ↗ |
| 2016-12-06 | Anderson Richard Rox | Director | A-Award | A | STRATA Skin Non-Qualified Stock Options | 75,000 | 0.55 | 41.3K | 75,000 | — | ↗ |
| 2016-11-28 | MCCANEY FRANK J | Director / Officer | P-Purchase | A | STRATA Skin Sciences Stock | 7,035 | 0.51 | 3.6K | 20,000 | — | ↗ |
| 2016-10-31 | MCCANEY FRANK J | Director / Officer | A-Award | A | Stock Option (right to buy) | 542,500 | 0.55 | 298.4K | 542,500 | — | ↗ |
| 2016-06-07 | Allgeier Christina L | Officer | A-Award | A | Stock Options | 100,000 | 0.75 | 75.0K | 100,000 | — | ↗ |
| 2016-03-11 | Broadfin Healthcare Master Fund Ltd | 10% Owner | S-Sale | D | Common Stock | 200,000 | 1.28 | 256.0K | 1,008,297 | — | ↗ |
| 2016-03-10 | Broadfin Healthcare Master Fund Ltd | 10% Owner | S-Sale | D | Common Stock | 25,000 | 1.50 | 37.5K | 1,224,297 | — | ↗ |
| 2016-02-25 | STEWART MICHAEL R | Director / Officer | A-Award | A | STRATA Stock Options | 125,000 | 1.31 | 163.8K | 125,000 | — | ↗ |
| 2015-12-15 | STEWART MICHAEL R | Officer | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2015-12-01 | Via LuAnn | Director | A-Award | A | MELA Stock Option | 75,000 | 1.18 | 88.5K | 75,000 | — | ↗ |
| 2015-12-01 | Swintek Kathryn B | Director | A-Award | A | MELA Stock Option | 75,000 | 1.18 | 88.5K | 75,000 | — | ↗ |
| 2015-12-01 | STONE DAVID K | Director | A-Award | A | MELA Stock Option | 75,000 | 1.18 | 88.5K | 75,000 | — | ↗ |
| 2015-12-01 | ODONNELL JEFFREY F | Director | A-Award | A | MELA Stock Option | 75,000 | 1.18 | 88.5K | 75,000 | — | ↗ |
| 2015-12-01 | NAVARRO SAMUEL E | Director | A-Award | A | Mela Stock Options | 75,000 | 1.18 | 88.5K | 75,000 | — | ↗ |
| 2015-12-01 | Anderson Richard Rox | Director | A-Award | A | MELA Stock Option | 75,000 | 1.18 | 88.5K | 75,000 | — | ↗ |
| 2015-11-09 | Allgeier Christina L | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-09-30 | ODONNELL JEFFREY F | Director | A-Award | A | MELA Stock Option | 500,000 | 1.14 | 570.0K | 500,000 | — | ↗ |
| 2015-09-30 | NAVARRO SAMUEL E | Director | A-Award | A | Mela Stock Options | 500,000 | 1.14 | 570.0K | 500,000 | — | ↗ |
| 2015-09-30 | Anderson Richard Rox | Director | A-Award | A | MELA Stock Option | 37,500 | 1.14 | 42.8K | 37,500 | — | ↗ |
| 2015-08-11 | Broadfin Capital, LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,274,297 | — | ↗ |
| 2015-06-22 | Broadfin Capital, LLC | 10% Owner | — | D | Senior Convertible Debenture | 20,000,000 | 0.00 | — | 0 | — | ↗ |
| 2015-02-03 | Cook Robert W. | Officer | A-Award | A | Stock Options | 5,000 | 5.60 | 28.0K | 5,000 | — | ↗ |
| 2014-12-31 | Cook Robert W. | Officer | P-Purchase | A | Common Stock | 10,000 | 1.23 | 12.3K | 10,000 | — | ↗ |
| 2014-12-15 | STEWART MICHAEL R | Director | A-Award | A | Stock Options | 375,000 | 1.31 | 491.3K | 375,000 | — | ↗ |
| 2014-12-09 | Phelan Mary | Officer | — | D | Stock options | 35,000 | 0.66 | 23.1K | 0 | — | ↗ |
| 2014-12-01 | Via LuAnn | Director | A-Award | A | Stock Options | 75,000 | 1.58 | 118.5K | 75,000 | — | ↗ |
| 2014-12-01 | Swintek Kathryn B | Director | A-Award | A | Stock Options | 75,000 | 1.58 | 118.5K | 75,000 | — | ↗ |
| 2014-12-01 | STONE DAVID K | Director | A-Award | A | Stock Options | 75,000 | 1.58 | 118.5K | 75,000 | — | ↗ |
| 2014-12-01 | ODONNELL JEFFREY F | Director | A-Award | A | Stock Options | 75,000 | 1.58 | 118.5K | 75,000 | — | ↗ |
| 2014-12-01 | NAVARRO SAMUEL E | Director | A-Award | A | Stock Options | 75,000 | 1.58 | 118.5K | 75,000 | — | ↗ |
| 2014-08-01 | STEWART MICHAEL R | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-07-24 | Broadfin Capital, LLC | 10% Owner | — | I | Common Stock Warrant | 1,559,454 | 2.45 | 3.82M | 0 | — | ↗ |
| 2014-05-22 | DIMUN ANTHONY J | Director | P-Purchase | A | Common Stock | 35,000 | 0.38 | 13.4K | 101,013 | — | ↗ |
| 2014-04-14 | Cook Robert W. | Officer | A-Award | A | Stock Options | 300,000 | 0.56 | 168.0K | 300,000 | — | ↗ |
| 2014-04-08 | Swintek Kathryn B | Director | A-Award | A | Stock Options | 7,813 | 0.54 | 4.2K | 7,813 | — | ↗ |
| 2014-04-08 | ODONNELL JEFFREY F | Director | A-Award | A | Stock Options | 7,813 | 0.54 | 4.2K | 7,813 | — | ↗ |
| 2014-04-08 | NAVARRO SAMUEL E | Director | A-Award | A | Stock Options | 3,787 | 0.54 | 2.0K | 3,787 | — | ↗ |
| 2014-04-08 | DIMUN ANTHONY J | Director | A-Award | A | Stock Options | 7,813 | 0.54 | 4.2K | 7,813 | — | ↗ |
| 2014-03-13 | NAVARRO SAMUEL E | Director | A-Award | A | Stock Options | 10,000 | 0.71 | 7.1K | 10,000 | — | ↗ |
| 2014-03-11 | NAVARRO SAMUEL E | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-03-06 | Phelan Mary | Officer | A-Award | A | Stock Options | 100,000 | 0.74 | 74.0K | 100,000 | — | ↗ |
| 2014-02-05 | Via LuAnn | Director | P-Purchase | A | Common Stock | 13,513 | 0.74 | 10.0K | 28,513 | — | ↗ |
| 2014-02-05 | Swintek Kathryn B | Director | P-Purchase | A | Common Stock | 13,513 | 0.74 | 10.0K | 33,513 | — | ↗ |
| 2014-02-05 | STONE DAVID K | Director | P-Purchase | A | Common Stock | 13,514 | 0.74 | 10.0K | 23,514 | — | ↗ |
| 2014-02-05 | ODONNELL JEFFREY F | Director | P-Purchase | A | Common Stock | 13,513 | 0.74 | 10.0K | 13,513 | — | ↗ |
| 2014-02-05 | DIMUN ANTHONY J | Director | P-Purchase | A | Common Stock | 13,513 | 0.74 | 10.0K | 13,513 | — | ↗ |
| 2014-02-05 | Crane Rosemary A | Director / Officer | P-Purchase | A | Common Stock | 67,570 | 0.74 | 50.0K | 67,570 | — | ↗ |
| 2014-02-05 | Coradini Robert | Director / Officer | P-Purchase | A | Common Stock | 67,567 | 0.74 | 50.0K | 139,024 | — | ↗ |
| 2014-02-05 | Broadfin Healthcare Master Fund Ltd | 10% Owner | — | I | Common Stock Warrant | 4,324,324 | 0.74 | 3.20M | 0 | — | ↗ |
| 2014-02-05 | Broadfin Capital, LLC | 10% Owner | — | D | Common Stock Warrant | 432,432 | 7.40 | 3.20M | 0 | — | ↗ |
| 2014-01-01 | ODONNELL JEFFREY F | Director | A-Award | A | Stock Options | 10,000 | 0.64 | 6.4K | 10,000 | — | ↗ |
| 2013-12-06 | Via LuAnn | Director | A-Award | A | Stock Options | 10,000 | 0.68 | 6.8K | 10,000 | — | ↗ |
| 2013-12-06 | Swintek Kathryn B | Director | A-Award | A | Stock Options | 10,000 | 0.68 | 6.8K | 10,000 | — | ↗ |
| 2013-12-06 | STONE DAVID K | Director | A-Award | A | Stock Options | 10,000 | 0.68 | 6.8K | 10,000 | — | ↗ |
| 2013-12-06 | MEADS MINDY C | Director | A-Award | A | Stock Options | 10,000 | 0.68 | 6.8K | 10,000 | — | ↗ |
| 2013-12-06 | Fabiani Mark D | Director | A-Award | A | Stock Options | 10,000 | 0.68 | 6.8K | 10,000 | — | ↗ |
| 2013-12-06 | Egger Anne M | Director | A-Award | A | Stock Options | 10,000 | 0.68 | 6.8K | 10,000 | — | ↗ |
| 2013-12-06 | DIMUN ANTHONY J | Director | A-Award | A | Stock Options | 10,000 | 0.68 | 6.8K | 10,000 | — | ↗ |
| 2013-12-06 | Coradini Robert | Director / Officer | A-Award | A | Stock Options | 10,000 | 0.68 | 6.8K | 10,000 | — | ↗ |
| 2013-11-11 | Crane Rosemary A | Director / Officer | A-Award | A | Stock Options | 400,000 | 0.70 | 280.0K | 400,000 | — | ↗ |
| 2013-10-01 | DIMUN ANTHONY J | Director | A-Award | A | Stock Options | 12,000 | 0.75 | 9.0K | 12,000 | — | ↗ |
| 2013-08-08 | Via LuAnn | Director | A-Award | A | Stock Option | 29,730 | 0.74 | 22.0K | 29,730 | — | ↗ |
| 2013-08-08 | Swintek Kathryn B | Director | A-Award | A | Stock Option | 32,432 | 0.74 | 24.0K | 32,432 | — | ↗ |
| 2013-08-08 | STONE DAVID K | Director | A-Award | A | Stock Option | 56,757 | 0.74 | 42.0K | 56,757 | — | ↗ |
| 2013-08-08 | MEADS MINDY C | Director | A-Award | A | Stock Option | 40,541 | 0.74 | 30.0K | 40,541 | — | ↗ |
| 2013-08-08 | Fabiani Mark D | Director | A-Award | A | Stock Option | 13,514 | 0.74 | 10.0K | 13,514 | — | ↗ |
| 2013-08-08 | Egger Anne M | Director | A-Award | A | Stock Option | 40,541 | 0.74 | 30.0K | 40,541 | — | ↗ |
| 2013-08-05 | Steinhart Richard I | Officer | A-Award | A | Stock Options | 141,304 | 0.92 | 130.0K | 141,304 | — | ↗ |
| 2013-06-28 | Coradini Robert | Director / Officer | P-Purchase | A | Common Stock | 15,000 | 0.99 | 14.9K | 30,000 | — | ↗ |
| 2013-06-27 | Egger Anne M | Director | P-Purchase | A | Common Stock | 11,000 | 0.90 | 9.9K | 16,350 | — | ↗ |
| 2013-06-27 | Coradini Robert | Director / Officer | P-Purchase | A | Common Stock | 172 | 0.87 | 149.47 | 15,000 | — | ↗ |
| 2013-06-26 | Via LuAnn | Director | P-Purchase | A | Common Stock | 15,000 | 0.79 | 11.9K | 15,000 | — | ↗ |
| 2013-06-25 | Steinhart Richard I | Officer | P-Purchase | A | Common Stock | 3,000 | 0.81 | 2.4K | 4,000 | — | ↗ |
| 2013-06-24 | Swintek Kathryn B | Director | P-Purchase | A | Common Stock | 17,000 | 0.73 | 12.4K | 20,000 | — | ↗ |
| 2013-06-24 | Coradini Robert | Director / Officer | P-Purchase | A | Common Stock | 9,900 | 0.72 | 7.1K | 31,357 | — | ↗ |
| 2013-06-21 | Swintek Kathryn B | Director | P-Purchase | A | Common Stock | 3,000 | 0.79 | 2.4K | 3,000 | — | ↗ |
| 2013-06-21 | Coradini Robert | Director / Officer | A-Award | A | Stock Options | 200,000 | 0.73 | 146.0K | 200,000 | — | ↗ |
| 2013-06-20 | MEADS MINDY C | Director | P-Purchase | A | Common Stock | 5,070 | 0.79 | 4.0K | 5,070 | — | ↗ |
| 2013-06-19 | STONE DAVID K | Director | P-Purchase | A | Common Stock | 10,000 | 0.82 | 8.2K | 10,000 | — | ↗ |
| 2013-05-03 | Gulfo Joseph V | Director / Officer | P-Purchase | A | Common Stock | 25,000 | 1.08 | 27.0K | 208,311 | — | ↗ |
| 2013-05-02 | Swintek Kathryn B | Director | A-Award | A | Stock Option | 7,500 | 1.06 | 8.0K | 7,500 | — | ↗ |
| 2013-04-25 | Swintek Kathryn B | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-04-25 | Steinhart Richard I | Officer | A-Award | A | Stock Option | 1,500 | 1.24 | 1.9K | 1,500 | — | ↗ |
| 2013-04-25 | Gulfo Joseph V | Director / Officer | A-Award | A | Stock Option | 1,000,000 | 1.24 | 1.24M | 1,000,000 | — | ↗ |
| 2013-03-13 | Gulfo Joseph V | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 1.15 | 23.0K | 183,311 | — | ↗ |
| 2013-01-15 | Kabelev Nikolai | Officer | M-Exempt | A | Common Stock | 2,886 | 1.00 | 2.9K | 4,761 | — | ↗ |
| 2012-12-14 | Via LuAnn | Director | A-Award | A | Stock Option | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2012-12-14 | STONE DAVID K | Director | A-Award | A | Stock Option | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2012-12-14 | MEADS MINDY C | Director | A-Award | A | Stock Option | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2012-12-14 | Goddard John Geoffrey | Director | A-Award | A | Stock Option | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2012-12-14 | Fabiani Mark D | Director | A-Award | A | Stock Option | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2012-12-14 | Egger Anne M | Director | A-Award | A | Stock Option | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2012-12-14 | Coradini Robert | Director | A-Award | A | Stock Option | 10,000 | 2.07 | 20.7K | 10,000 | — | ↗ |
| 2012-11-12 | Gulfo Joseph V | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.68 | 26.8K | 163,311 | — | ↗ |
| 2012-05-17 | Goddard John Geoffrey | Director | P-Purchase | A | Common Stock | 10,000 | 2.90 | 29.0K | 10,000 | — | ↗ |
| 2012-05-08 | Gulfo Joseph V | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 3.88 | 38.8K | 153,311 | — | ↗ |
| 2012-04-26 | Via LuAnn | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-55.0K
Shares Outstanding
4.65M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Dolev Rafaeli President, Chief Executive Officer and Vice-Chairman of the Board | 508.9K | — | — | — | 63.7K | 28.8K | 601.4K | 0.00% | ↗ |
| 2 | 2024 | Shmuel Gov Chief Operating Officer | 324.9K | — | — | — | 120.0K | 25.8K | 470.7K | 0.00% | ↗ |
| 3 | 2024 | Robert Moccia Former Director, President and Chief Executive Officer | — | — | — | — | — | 322.8K | 322.8K | 0.00% | ↗ |
| 4 | 2024 | Chris Lesovitz Chief Financial Officer | 189.6K | — | — | — | 71.3K | 16.3K | 277.2K | 0.00% | ↗ |
| 5 | 2024 | John Gillings Chief Accounting Officer | 82.2K | — | — | 56.5K | — | 5.0K | 143.7K | 39.30% | ↗ |
| 6 | 2023 | Robert Moccia Former Director, President and Chief Executive Officer | 461.1K | — | — | 102.2K | 284.5K | 201.3K | 1.05M | 9.74% | ↗ |
| 7 | 2023 | Chris Lesovitz, Chief Financial Officer | 282.3K | — | — | 208.7K | 187.5K | 23.4K | 701.9K | 29.73% | ↗ |
| 8 | 2023 | Chris Lesovitz Chief Financial Officer | 282.3K | — | — | 208.7K | 187.5K | 23.4K | 701.9K | 29.73% | ↗ |
| 9 | 2023 | Shmuel Gov Chief Operating Officer | 303.8K | — | — | 219.5K | 135.2K | 25.2K | 683.8K | 32.10% | ↗ |
| 10 | 2023 | Dolev Rafaeli President, Chief Executive Officer and Vice-Chairman of the Board | 67.3K | — | — | 590.0K | — | 4.9K | 662.6K | 89.04% | ↗ |
| 11 | 2022 | Robert Moccia, Director, President and Chief Executive Officer | 510.7K | — | — | 144.9K | 299.7K | 27.2K | 982.5K | 14.75% | ↗ |
| 12 | 2022 | Robert Moccia Former Director, President and Chief Executive Officer | 510.7K | — | — | 144.9K | 299.7K | 27.2K | 982.5K | 14.75% | ↗ |
| 13 | 2022 | Shmuel Gov Chief Operating Officer | 290.0K | — | — | 65.8K | 154.9K | 25.6K | 536.3K | 12.27% | ↗ |
| 14 | 2022 | Shmuel Gov, Senior Vice President and General Manager | 290.0K | — | — | 65.8K | 154.9K | 25.6K | 536.3K | 12.27% | ↗ |
| 15 | 2022 | Chris Lesovitz, Chief Financial Officer | 250.0K | — | — | 94.0K | 42.5K | 21.3K | 407.8K | 23.05% | ↗ |
| 16 | 2021 | Robert Moccia Director, President and Chief Executive Officer as of 3/1/21 | 416.3K | — | — | 2.10M | 299.7K | 18.8K | 3.56M | 59.08% | ↗ |
| 17 | 2021 | Robert Moccia, Director, President and Chief Executive Officer | 403.8K | — | — | 1.78M | — | 18.8K | 2.21M | 80.85% | ↗ |
| 18 | 2021 | Chris Lesovitz, Chief Financial Officer as of 10/18/2021 | 100.3K | — | — | 348.3K | 42.5K | 3.0K | 615.8K | 56.55% | ↗ |
| 19 | 2021 | Chris Lesovitz, Chief Financial Officer | 97.3K | — | — | 296.5K | — | 3.0K | 396.8K | 74.71% | ↗ |
| 20 | 2021 | Shmuel Gov, Senior Vice President and General Manager | 264.5K | — | — | — | 55.4K | 18.6K | 338.4K | 0.00% | ↗ |
| 21 | 2021 | Matt Hill, Chief Financial Officer until 10/18/2021 | 284.9K | — | — | — | — | 17.7K | 302.6K | 0.00% | ↗ |
| 22 | 2021 | Dolev Rafaeli, Director, President and Chief Executive Officer until 2/28/21 | 271.2K | — | — | — | — | 11.5K | 282.7K | 0.00% | ↗ |
| 23 | 2020 | Dolev Rafaeli, Director, President and Chief Executive Officer until 2/28/21 | 412.0K | — | — | — | 157.9K | 23.4K | 593.3K | 0.00% | ↗ |
| 24 | 2020 | Matthew C. Hill, Chief Financial Officer | 246.9K | — | — | 166.2K | 47.5K | 16.2K | 476.8K | 34.85% | ↗ |
| 25 | 2020 | Dolev Rafaeli , Director, President and Chief Executive Officer | 400.0K | — | — | — | — | 23.4K | 423.4K | 0.00% | ↗ |
| 26 | 2020 | Matt Hill, Chief Financial Officer until 10/18/2021 | 253.5K | — | — | — | 47.5K | 16.2K | 317.2K | 0.00% | ↗ |
| 27 | 2019 | Dolev Rafaeli , Director, President and Chief Executive Officer | 400.0K | — | — | 466.5K | 277.9K | 23.2K | 1.17M | 39.95% | ↗ |
| 28 | 2019 | Matthew C. Hill , Chief Financial Officer | 240.0K | — | — | 233.3K | 149.3K | 16.0K | 638.5K | 36.53% | ↗ |
| 29 | 2019 | Matthew C. Hill, Chief Financial Officer | 240.0K | — | — | 233.3K | 149.3K | 16.0K | 638.5K | 36.53% | ↗ |
| 30 | 2018 | Dolev Rafaeli , Director, President and Chief Executive Officer | 289.1K | — | — | 2.22M | 142.9K | 36.6K | 2.69M | 82.59% | ↗ |
| 31 | 2018 | Matthew C. Hill , Chief Financial Officer | 149.2K | — | — | 225.3K | 40.6K | 2.8K | 417.8K | 53.91% | ↗ |
| 32 | 2018 | Francis J. McCaney , Director, President and Chief Executive Officer | 386.2K | — | — | — | — | 6.1K | 392.3K | 0.00% | ↗ |
| 33 | 2018 | Christina L. Allgeier | 18.3K | — | — | — | — | 30.0K | 48.3K | 0.00% | ↗ |
| 34 | 2017 | Francis J. McCaney , Director, President and Chief Executive Officer | 375.0K | — | — | — | — | 13.2K | 388.2K | 0.00% | ↗ |
| 35 | 2017 | Christina L. Allgeier | 220.0K | — | — | — | — | 13.6K | 233.6K | 0.00% | ↗ |
| 36 | 2017 | Christina L. Allgeier , Chief Financial Officer and Treasurer | 220.0K | — | — | — | — | 13.6K | 233.6K | 0.00% | ↗ |
| 37 | 2016 | Michael R. Stewart , Former Director, President and Chief Executive Officer | 344.2K | — | — | — | — | 388.7K | 732.9K | 0.00% | ↗ |
| 38 | 2016 | Christina L. Allgeier , Chief Financial Officer and Treasurer | 200.0K | 25.5K | — | 37.6K | — | 13.5K | 276.6K | 13.59% | ↗ |
| 39 | 2016 | Francis J. McCaney , Director, President and Chief Executive Officer | 56.7K | — | — | 150.3K | — | 1.0K | 208.0K | 72.26% | ↗ |
| 40 | 2015 | Michael R. Stewart , Former Director, President and Chief Executive Officer | 313.6K | 255.0K | 109.0K | — | — | 37.4K | 715.0K | 15.24% | ↗ |
| 41 | 2015 | Michael R. Stewart , Director, President and Chief Executive Officer | 313.6K | 255.0K | 109.0K | — | — | 37.4K | 715.0K | 15.24% | ↗ |
| 42 | 2015 | Robert W. Cook , Former Chief Financial Officer, Secretary and Treasurer | 247.5K | — | — | — | — | 208.3K | 455.8K | 0.00% | ↗ |
| 43 | 2015 | Christina L. Allgeier , Chief Financial Officer and Treasurer | 90.7K | 30.0K | — | — | — | 7.1K | 127.8K | 0.00% | ↗ |
| 44 | 2014 | Michael R. Stewart Director, President and | 14.1K | — | — | 712.5K | — | 18.3K | 744.9K | 95.65% | ↗ |
| 45 | 2014 | Michael R. Stewart , Director, President and Chief Executive Officer | 14.1K | — | — | 712.5K | — | 18.3K | 744.9K | 95.65% | ↗ |
| 46 | 2014 | Rose A. Crane Former Director, | 272.9K | — | — | — | — | 150.0K | 422.9K | 0.00% | ↗ |
| 47 | 2014 | Robert W. Cook Chief Financial Officer, | 179.0K | 15.0K | — | 190.0K | — | — | 384.0K | 49.48% | ↗ |
| 48 | 2014 | Robert W. Cook , Former Chief Financial Officer, Secretary and Treasurer | 179.0K | 15.0K | — | 190.0K | — | — | 384.0K | 49.48% | ↗ |
| 49 | 2013 | Joseph V. Gulfo, M.D. Former Chairman, President and Chief Executive Officer | 179.7K | — | — | 1.23M | — | 5.4K | 1.42M | 86.95% | ↗ |
| 50 | 2013 | Rose A. Crane Director, President and Chief Executive Officer | 43.2K | — | — | 480.0K | — | — | 523.2K | 91.74% | ↗ |
| 51 | 2013 | Rose A. Crane Former Director, | 43.2K | — | — | 480.0K | — | — | 523.2K | 91.74% | ↗ |
| 52 | 2013 | Richard I. Steinhart Former Sr. Vice President Finance, Chief Financial Officer, Secretary and Treasurer | 243.1K | — | 4.6K | 98.1K | — | 97.5K | 443.3K | 23.16% | ↗ |
| 53 | 2013 | Robert C. Coradini Director and Interim President and Chief Executive Officer | 82.7K | — | — | 113.6K | — | 72.9K | 269.2K | 42.19% | ↗ |
| 54 | 2013 | Michael R. Stewart Director, President and | — | — | — | — | — | — | — | — | ↗ |
| 55 | 2013 | Robert W. Cook Chief Financial Officer, | — | — | — | — | — | — | — | — | ↗ |
| 56 | 2012 | Joseph V. Gulfo, M.D., Chairman, President and Chief Executive Officer | 313.6K | — | — | — | — | 45.4K | 359.0K | 0.00% | ↗ |
| 57 | 2012 | Joseph V. Gulfo, M.D. Former Chairman, President and Chief Executive Officer | 313.6K | — | — | — | — | 45.4K | 359.0K | 0.00% | ↗ |
| 58 | 2012 | Richard I. Steinhart Former Sr. Vice President Finance, Chief Financial Officer, Secretary and Treasurer | 257.7K | 25.0K | — | — | — | — | 282.7K | 0.00% | ↗ |
| 59 | 2012 | Richard I. Steinhart, Sr. Vice President Finance, Chief Financial Officer, Secretary and Treasurer | 257.7K | 25.0K | — | — | — | — | 282.7K | 0.00% | ↗ |
| 60 | 2012 | Robert C. Coradini Director and Interim President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 61 | 2011 | Richard I. Steinhart, Vice President Finance, Chief Financial Officer, Secretary and Treasurer | 221.8K | 10.0K | — | 253.0K | — | — | 484.8K | 52.19% | ↗ |
| 62 | 2011 | Richard I. Steinhart, Sr. Vice President Finance, Chief Financial Officer, Secretary and Treasurer | 221.8K | 10.0K | — | 253.0K | — | — | 484.8K | 52.19% | ↗ |
| 63 | 2011 | Nikolai Kabelev, Vice President, Research And Development | 190.0K | — | — | 180.9K | — | — | 370.9K | 48.77% | ↗ |
| 64 | 2011 | Joseph V. Gulfo, M.D., Chairman, President and Chief Executive Officer | 313.6K | — | — | — | — | 45.4K | 359.0K | 0.00% | ↗ |
| 65 | 2011 | Tina Cheng-Avery, Vice President Commercialization | 126.6K | — | — | — | — | — | 126.6K | 0.00% | ↗ |
| 66 | 2010 | Joseph V. Gulfo, M.D., Chairman, President and Chief Executive Officer | 313.6K | — | — | — | — | 45.4K | 359.0K | 0.00% | ↗ |
| 67 | 2010 | Nikolai Kabelev, Vice President, Research And Development | 189.3K | 10.0K | — | 115.3K | — | — | 314.5K | 36.65% | ↗ |
| 68 | 2010 | Richard I. Steinhart, Sr. Vice President Finance, Chief Financial Officer, Secretary and Treasurer | 221.3K | 10.0K | — | 76.1K | — | — | 307.3K | 24.75% | ↗ |
| 69 | 2010 | Richard I. Steinhart, Vice President Finance, Chief Financial Officer, Secretary and Treasurer | 221.3K | 10.0K | — | 76.1K | — | — | 307.3K | 24.75% | ↗ |
| 70 | 2010 | Tina Cheng-Avery, Vice President Commercialization | 209.6K | 10.0K | — | — | — | — | 219.6K | 0.00% | ↗ |
| 71 | 2010 | Joseph V. Gulfo, M.D., President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 72 | 2010 | Richard I. Steinhart, Vice President Finance, Chief Financial Officer, | — | — | — | — | — | — | — | — | ↗ |
| 73 | 2010 | Christiano Butler, Vice President Operations | — | — | — | — | — | — | — | — | ↗ |
| 74 | 2010 | Tina Cheng-Avery, Vice President of Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 75 | 2009 | Joseph V. Gulfo, M.D., Chairman, President and Chief Executive Officer | 306.7K | 150.0K | — | — | — | 60.7K | 517.4K | 0.00% | ↗ |
| 76 | 2009 | Tina Cheng-Avery, Vice President Commercialization | 205.6K | 30.0K | — | — | — | — | 235.6K | 0.00% | ↗ |
| 77 | 2009 | Richard I. Steinhart, Vice President Finance, Chief Financial Officer, Secretary and Treasurer | 217.9K | 10.0K | — | — | — | — | 227.9K | 0.00% | ↗ |
| 78 | 2009 | Nikolai Kabelev, Vice President, Research And Development | 184.3K | 20.0K | — | — | — | — | 204.3K | 0.00% | ↗ |
| 79 | 2009 | Tina Cheng-Avery, Vice President of Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 80 | 2009 | Richard I. Steinhart, Vice President Finance, Chief Financial Officer, | — | — | — | — | — | — | — | — | ↗ |
| 81 | 2009 | Joseph V. Gulfo, M.D., President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 82 | 2009 | Christiano Butler, Vice President Operations | — | — | — | — | — | — | — | — | ↗ |
| 83 | 2009 | Tina Cheng — Avery, Vice President of Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 84 | 2008 | Tina Cheng-Avery, Vice President of Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 85 | 2008 | Richard I. Steinhart, Vice President Finance, Chief Financial Officer, | — | — | — | — | — | — | — | — | ↗ |
| 86 | 2008 | Nikolai Kabelev, Vice President, Research And Development | — | — | — | — | — | — | — | — | ↗ |
| 87 | 2008 | Tina Cheng — Avery, Vice President of Commercialization | — | — | — | — | — | — | — | — | ↗ |
| 88 | 2008 | Nikolai Kabelev Vice President, Research and Development | — | — | — | — | — | — | — | — | ↗ |
| 89 | 2008 | Tina Cheng — Avery | — | — | — | — | — | — | — | — | ↗ |
| 90 | 2008 | Jon I Klippel Vice President, Marketing Operations | — | — | — | — | — | — | — | — | ↗ |
| 91 | 2008 | Joseph V. Gulfo, M.D., President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 92 | 2008 | Christiano Butler, Vice President Operations | — | — | — | — | — | — | — | — | ↗ |
| 93 | 2008 | Richard I. Steinhart Vice President Finance, Chief Financial Officer, Secretary and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 94 | 2008 | Joseph V. Gulfo, M.D. President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 95 | 2008 | Christiano Butler Vice President Operations | — | — | — | — | — | — | — | — | ↗ |
| 96 | 2007 | Joseph V. Gulfo, M.D. President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 97 | 2007 | Richard I. Steinhart, Vice President Finance, Chief Financial Officer, | — | — | — | — | — | — | — | — | ↗ |
| 98 | 2007 | Nikolai Kabelev, Vice President, Research And Development | — | — | — | — | — | — | — | — | ↗ |
| 99 | 2007 | Joseph V. Gulfo, M.D., President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 100 | 2007 | Christiano Butler Vice President Operations | — | — | — | — | — | — | — | — | ↗ |
| 101 | 2007 | Richard I. Steinhart Vice President Finance, Chief Financial Officer, Secretary and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 102 | 2007 | Jon I Klippel Vice President, Marketing Operations | — | — | — | — | — | — | — | — | ↗ |
| 103 | 2007 | Nikolai Kabelev Vice President, Research and Development | — | — | — | — | — | — | — | — | ↗ |
| 104 | 2007 | Joseph V. Gulfo, M.D., M.B.A. President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 105 | 2007 | Nikolai Kabelev | — | — | — | — | — | — | — | — | ↗ |
| 106 | 2006 | Jon I Klippel Vice President, Marketing Operations | — | — | — | — | — | — | — | — | ↗ |
| 107 | 2006 | Christiano Butler Vice President Operations | — | — | — | — | — | — | — | — | ↗ |
| 108 | 2006 | Joseph V. Gulfo, M.D., M.B.A. President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 109 | 2006 | William Bronner | — | — | — | — | — | — | — | — | ↗ |
| 110 | 2006 | Richard I. Steinhart | — | — | — | — | — | — | — | — | ↗ |
| 111 | 2006 | Jon. I. Klippel | — | — | — | — | — | — | — | — | ↗ |
| 112 | 2006 | Karen Krumeich | — | — | — | — | — | — | — | — | ↗ |
| 113 | 2006 | Christiano Butler | — | — | — | — | — | — | — | — | ↗ |
| 114 | 2006 | Joseph V. Gulfo, M.D., M.B.A. | — | — | — | — | — | — | — | — | ↗ |
| 115 | 2006 | Joseph V. Gulfo, M.D. President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 116 | 2006 | Richard I. Steinhart Vice President Finance, Chief Financial Officer, Secretary and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 117 | 2005 | Gerald Wagner, Ph.D. Acting Chief Operating Officer | — | — | — | — | — | 193.8K | 193.8K | 0.00% | ↗ |
| 118 | 2005 | Marek Elbaum, Ph.D. Founder and former Chief Science and Technology Officer | 75.6K | — | — | — | — | 107.3K | 182.9K | 0.00% | ↗ |
| 119 | 2005 | Joseph V. Gulfo, M.D. President and Chief Executive Officer | 175.0K | — | — | — | — | — | 175.0K | 0.00% | ↗ |
| 120 | 2005 | Karen Krumeich Vice President Finance, Chief Financial Officer | 165.0K | — | — | — | — | — | 165.0K | 0.00% | ↗ |
| 121 | 2005 | Jon I. Klippel Vice President Marketing and Sales | 135.0K | — | — | — | — | — | 135.0K | 0.00% | ↗ |
| 122 | 2005 | William Bronner Vice President, Legal Counsel and Compliance | 120.0K | — | — | — | — | 3.6K | 123.6K | 0.00% | ↗ |
| 123 | 2004 | Joseph V. Gulfo, M.D. President and Chief Executive Officer | 173.7K | — | — | — | — | 37.2K | 210.9K | 0.00% | ↗ |
| 124 | 2004 | Marek Elbaum, Ph.D. Founder and former Chief Science and Technology Officer | 173.5K | — | — | — | — | 3.0K | 176.6K | 0.00% | ↗ |
| 125 | 2004 | William Bronner Vice President, Legal Counsel and Compliance | 132.6K | — | — | — | — | 3.0K | 135.6K | 0.00% | ↗ |
| 126 | 2004 | Jon I. Klippel Vice President Marketing and Sales | 9.3K | — | — | — | — | — | 9.3K | 0.00% | ↗ |
| 127 | 2004 | Gerald Wagner, Ph.D. Acting Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2004 | Karen Krumeich Vice President Finance, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 129 | 2003 | William Bronner Vice President, Legal Counsel and Compliance | 106.3K | — | — | — | — | — | 106.3K | 0.00% | ↗ |
| 130 | 2003 | Marek Elbaum, Ph.D. Founder and former Chief Science and Technology Officer | 81.1K | — | — | — | — | — | 81.1K | 0.00% | ↗ |
| 131 | 2003 | Joseph V. Gulfo, M.D. President and Chief Executive Officer | — | — | — | — | — | 19.9K | 19.9K | 0.00% | ↗ |
| 132 | 2003 | Karen Krumeich Vice President Finance, Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 133 | 2003 | Gerald Wagner, Ph.D. Acting Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 134 | 2003 | Jon I. Klippel Vice President Marketing and Sales | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dolev Rafaeli | President, Chief Executive Officer & Vice-Chairman | 984.0K | — |
| Michael R. Stewart | Independent Consultant | 732.9K | male |
| Shmuel | Chief Operating Officer | 546.6K | male |
| John Gillings | Principal Financial Officer & Chief Accounting Officer | 280.2K | male |
| Jay Sturm | General Counsel & Corporate Secretary | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SSKN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
